Skip to content

The Oncology Institute, Inc. TOI Lessee Operating Lease Liability Undiscounted Excess Amount

Lessee Operating Lease Liability Undiscounted Excess Amount at other companies

Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX

Other financials

Income statement

See full
Revenue$147.4M+41.2%
Operating income-$6.5M+34.3%
Net income-$2.5M+87.3%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$30.3M-23.8%
Total debt$104.9M+2.5%
Total equity-$16.3M-421%
Total assets$168.2M+2.6%

Cash flow

See full
Operating cash flow-$2.2M+55.6%
CapEx$1.0M+218%
Free cash flow-$3.3M+38.7%

Valuation

See full
Market cap$511.91M+133%
Enterprise value$586.58M+108%
P/S0.9×+0.4×

Profitability

See full
Operating margin-6%-2.1pp
Net margin-8%-2.7pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-277.6%-700pp
Debt / equity20.2×+17.3×
Current ratio1.5×-0.3×

Where this comes from

Reported directly by The Oncology Institute, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s lessee operating lease liability undiscounted excess amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Oncology Institute, Inc.'s lessee operating lease liability undiscounted excess amount?
The Oncology Institute, Inc. (TOI) reported lessee operating lease liability undiscounted excess amount of $3.97M in Q1 2026.
How has The Oncology Institute, Inc.'s lessee operating lease liability undiscounted excess amount changed year-over-year?
The Oncology Institute, Inc.'s lessee operating lease liability undiscounted excess amount decreased by 16.5% year-over-year, from $4.75M to $3.97M.